Oxidized-Multiwalled Carbon Nanotubes as Non-Toxic Nanocarriers for Hydroxytyrosol Delivery in Cells.
Panagiota ZygouriAntrea-Maria AthinodorouKonstantinos SpyrouYannis Vasileios SimosMohammed SubratiGeorgios AsimakopoulosKonstantinos C VasilopoulosPatra VezyrakiDimitrios PeschosKonstantinos Ioannis TsamisDimitrios Panagiotis GournisPublished in: Nanomaterials (Basel, Switzerland) (2023)
Carbon nanotubes (CNTs) possess excellent physicochemical and structural properties alongside their nano dimensions, constituting a medical platform for the delivery of different therapeutic molecules and drug systems. Hydroxytyrosol (HT) is a molecule with potent antioxidant properties that, however, is rapidly metabolized in the organism. HT immobilized on functionalized CNTs could improve its oral absorption and protect it against rapid degradation and elimination. This study investigated the effects of cellular oxidized multiwall carbon nanotubes (oxMWCNTs) as biocompatible carriers of HT. The oxidation of MWCNTs via H 2 SO 4 and HNO 3 has a double effect since it leads to increased hydrophilicity, while the introduced oxygen functionalities can contribute to the delivery of the drug. The in vitro effects of HT, oxMWCNTS, and oxMWCNTS functionalized with HT (oxMWCNTS_HT) were studied against two different cell lines (NIH/3T3 and Tg/Tg). We evaluated the toxicity (MTT and clonogenic assay), cell cycle arrest, and reactive oxygen species (ROS) formation. Both cell lines coped with oxMWCNTs even at high doses. oxMWCNTS_HT acted as pro-oxidants in Tg/Tg cells and as antioxidants in NIH/3T3 cells. These findings suggest that oxMWCNTs could evolve into a promising nanocarrier suitable for targeted drug delivery in the future.
Keyphrases
- carbon nanotubes
- cell cycle arrest
- drug delivery
- cell death
- reactive oxygen species
- induced apoptosis
- cancer therapy
- pi k akt
- drug release
- high throughput
- oxidative stress
- healthcare
- anti inflammatory
- dna damage
- quantum dots
- ionic liquid
- signaling pathway
- nitric oxide
- adverse drug
- current status
- molecularly imprinted
- low density lipoprotein
- single cell